Business Context and Reporting Period
This Form 8-K is filed by Oncocyte Corporation (trading symbol: OCX) on May 11, 2023. The filing primarily serves to announce the Company's financial results for the three months ended March 31, 2023, and to disclose a significant executive departure. Note: The input metadata referenced "Insight Molecular Diagnostics Inc.," but the filing text explicitly identifies the registrant as Oncocyte Corporation.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Item 2.02 states that the financial results for the three months ended March 31, 2023, are detailed in a press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the provided text.
Material Changes and Executive Departure
- Executive Departure: Anish John, Chief Financial Officer, announced his departure effective June 15, 2023.
- Reason: Mr. John intends to pursue other opportunities. The Company stated there were no disagreements regarding operations, policies, or practices.
- Succession: The Company has commenced a search for a qualified replacement.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, or management commentary regarding future financial performance, as these details are contained within the referenced Exhibit 99.1. The filing includes a standard disclaimer that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, limiting liability for forward-looking statements.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2023 revenue, net loss, and cash position figures.
- Monitor future announcements regarding the appointment of a new Chief Financial Officer.
- Verify the Company's liquidity status and runway given the recent executive transition.